Dramatic Growth In DNA-Based Forensics Doesn't Translate Into Job Opportunities

Government and private labs are springing up to accommodate expanded use of genetic evidence, but retraining existing workers. In less than a decade since DNA analysis brought forensic science into a new era, the growth of the discipline--as an evidentiary tool as well as an industry--has been massive, as more and more high-profile cases hinge upon the evidence it provides. Yet the phenomenal expansion of its use in courts around the United States is not translating into new entreprene

Written byKaren Young Kreeger
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


Government and private labs are springing up to accommodate expanded use of genetic evidence, but retraining existing workers.
In less than a decade since DNA analysis brought forensic science into a new era, the growth of the discipline--as an evidentiary tool as well as an industry--has been massive, as more and more high-profile cases hinge upon the evidence it provides. Yet the phenomenal expansion of its use in courts around the United States is not translating into new entrepreneurial or employment opportunities, researchers and industry observers contend, for a variety of reasons.

"The bottom line is that the availability of DNA testing is increasing, and as the supply of labs increases, so does the demand," maintains Mark Stolorow, director of operations at Germantown, Md.-based Cellmark Diagnostics, a publicly traded business unit of pharmaceutical firm Zeneca Inc. that performs DNA analysis. "The demand is totally elastic."

To fill that demand personnelwise, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies